AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Noveris Health Sciences Inc.
Video analysis: MYCOF
All videosNo video analysis for this stock yet. Request one from our team.
News: MYCOF
Noveris Health Sciences Announces Results of 2026 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces the results of its annual general and special meeting of shareholders held on September 4, 2026 (the "Meeting"). A total of 21,697,593 common shares of the Company were represented at the Meeting, representing approximately 37.06% of the 58,548,051 common shares issued and outstanding and entitled to vote at the Meeting.
Noveris Health Sciences Announces Proposed Private Placement of Convertible Debentures for up to $500,000
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") is pleased to announce its intention to complete a non-brokered private placement of convertible debentures of the Company (the "Debentures") in an aggregate principal amount of up to $500,000, issuable in increments of $1,000 principal amount, for aggregate gross proceeds of up to $500,000 (the "Offering"). The Offering is expected to close on or about August 28, 2026 (the "Closing Date").
Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same.
Noveris Health Sciences Inc. Unaware of Any Material Change
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2026) - At the request of CIRO, Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. Noveris is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation.
Noveris Health Sciences Joins BioAlberta
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) (the "Company" or "Noveris") announces that it has become a member of BioAlberta, a not-for-profit industry association representing Alberta's life sciences community. BioAlberta supports its members through industry development, educational and networking activities, and engagement on matters affecting Alberta's life sciences sector.
Noveris Health Sciences Joins the Biotechnology Innovation Organization (BIO)
VANCOUVER, BC, Canada – TheNewswire - July 17, 2026 — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) (“Noveris” or the “Company”) is pleased to announce that it has joined the Biotechnology Innovation Organization (“BIO”), the world's largest advocacy association representing biotechnology companies, academic and research institutions, state and regional biotechnology centers and related organizations across the United States and in more than 35 other countries. By joining BIO, Noveris is strengthening its participation in the global biotechnology ecosystem and expanding opportunities to engage with industry leaders, strategic partners, investors and policymakers across the United States and internationally. The Company believes that membership in BIO will support greater visibility for Noveris within the broader biotechnology and life sciences community while providing access to BIO's policy committees, investor and partnering events, industry research and cost-savings programs that help foster collaboration and commercialization.
Noveris Health Sciences Joins Life Sciences BC
VANCOUVER, BC, Canada – TheNewswire - July 14, 2026 — Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) ("Noveris" or the "Company") is pleased to announce that, effective July 13, 2026, it has joined Life Sciences British Columbia ("Life Sciences BC" or "LSBC"), the not-for-profit industry association that supports and represents British Columbia's life sciences community through leadership, investment, advocacy and promotion. By joining LSBC, Noveris is strengthening its participation in British Columbia's life sciences ecosystem and expanding opportunities to engage with innovators, strategic partners, investors, advisors and other sector stakeholders across the province. The Company believes that membership in LSBC will support greater visibility for Noveris within the local and national life sciences community while providing access to networking, industry programming and initiatives that help foster collaboration and commercialization.
Noveris Health Sciences Announces Upcoming AGM and Record Date, and receipt of CSE Notice
VANCOUVER, BC, Canada – TheNewswire - June 29, 2026 — Noveris Health Sciences Inc. (CSE: NVRS; FSE: 0NF0; OTC: MYCOF) (“ Noveris ” or the “ Company ”) is pleased to announce that its annual general meeting of shareholders (the " Meeting ") will be held on September 4, 2026 at 1890-1075 West Georgia Street, Vancouver, British Columbia. The record date for the meeting has been set for July 21, 2026. At the Meeting, shareholders of the Company will be asked to consider and, if deemed advisable, approve the following matters:
